Published in Microbiol Immunol on January 01, 1992
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol (1990) 3.22
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol (2001) 2.91
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol (1995) 2.78
Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (2000) 2.66
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg (1987) 2.54
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med (1989) 2.46
Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum (2000) 2.41
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
Pre-injury neuro-psychiatric medication use, alone or in combination with cardiac medications, may affect outcomes in trauma patients. J Postgrad Med (2014) 2.16
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol (1995) 2.02
Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med (1997) 2.01
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol (2013) 1.92
Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med (1988) 1.90
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am (2006) 1.89
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol (1992) 1.84
Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg (1988) 1.81
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol (1999) 1.78
Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst (1995) 1.76
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Early tracheostomy for primary airway management in the surgical critical care setting. Surgery (1990) 1.73
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer (1998) 1.65
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol (1994) 1.60
Long-term visual changes following pituitary irradiation. Int J Radiat Oncol Biol Phys (1995) 1.58
Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol (1999) 1.58
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest (1998) 1.58
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis (1995) 1.56
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol (1997) 1.53
Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol (2001) 1.52
Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood (1997) 1.52
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol (1994) 1.49
Retained surgical foreign bodies: a comprehensive review of risks and preventive strategies. Scand J Surg (2009) 1.49
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology (2007) 1.47
Biotic and abiotic factors affecting plasmid transfer in Escherichia coli strains. Appl Environ Microbiol (1992) 1.46
Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst (1990) 1.42
Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis (1992) 1.42
Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. Cancer (1998) 1.40
[Resistance in Haemophilus influenzae in Spain. 2d study (1990)]. Enferm Infecc Microbiol Clin (1993) 1.39
Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol (1994) 1.39
Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol (1988) 1.37
2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis (1993) 1.37
ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res (1991) 1.36
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol (1993) 1.34
Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res (1987) 1.34
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg (1998) 1.33
A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol (1993) 1.32
Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol (1988) 1.31
Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med (1990) 1.31
Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys (1993) 1.28
Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer (1986) 1.26
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia (2011) 1.26
Staphylococcus schleiferi: a new opportunistic pathogen. Clin Infect Dis (1993) 1.26
Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) (1992) 1.25
Pneumonia: incidence, risk factors, and outcome in injured patients. J Trauma (1991) 1.22
Influence of human immunodeficiency virus-infected maternal environment on development of infant interleukin-12 production. J Infect Dis (2000) 1.21
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol (1997) 1.19
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol (2000) 1.19
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res (1990) 1.19
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J (2009) 1.18
Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma. Ann Thorac Surg (1991) 1.18
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol (1994) 1.18
Recombinase-activating gene (RAG) 2-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient mice. Proc Natl Acad Sci U S A (2000) 1.17
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol (2008) 1.17
Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer (1995) 1.16
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis (1994) 1.15
Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest (1991) 1.15
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol (1989) 1.14
Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988. Am J Clin Oncol (2000) 1.14
Complications associated with pulmonary artery catheters: a comprehensive clinical review. Scand J Surg (2009) 1.14
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res (2000) 1.13
RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene (1994) 1.12
Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg (1992) 1.12
Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol (1988) 1.11
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol (2013) 1.11
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer (1996) 1.11
Importance of tumor pathology and morphology in patients with surgically resected colon cancer. Findings from the Gastrointestinal Tumor Study Group. Cancer (1986) 1.10
Serratia rubidaea as an invasive pathogen. J Clin Microbiol (1996) 1.09
Renal carcinoma in mother and daughter. Cancer (1972) 1.09
Use of complementary medicine by adult patients participating in HIV/AIDS clinical trials. J Altern Complement Med (2000) 1.09
Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol (2006) 1.07
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol (1994) 1.07
Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol (1993) 1.07
Novel transglutaminase-1 mutations and genotype-phenotype investigations of 104 patients with autosomal recessive congenital ichthyosis in the USA. J Med Genet (2008) 1.06
Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol (2000) 1.06
Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes Cancer (1991) 1.05
An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood (2000) 1.05